Spots Global Cancer Trial Database for Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Official Title: A Phase 1b, Open-Label Study of Sorafenib With BIIB022 in Subjects With Advanced Hepatocellular Carcinoma
Study ID: NCT00956436
Conditions
Study Description
Brief Summary: This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Resesarch Site, Denver, Colorado, United States
Resesarch Site, Ocoee, Florida, United States
Resesarch Site, Indianapolis, Indiana, United States
Resesarch Site, Boston, Massachusetts, United States
Resesarch Site, New York, New York, United States
Resesarch Site, Norfolk, Virginia, United States
Resesarch Site, Singapore, , Singapore
Resesarch Site, Tainan, , Taiwan
Resesarch Site, Taipei, , Taiwan
Resesarch Site, Tao-Yuan, , Taiwan
Resesarch Site, Edgbaston, Birmingham, United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
